These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 23251413)

  • 1. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.
    Corcoran C; Rani S; O'Brien K; O'Neill A; Prencipe M; Sheikh R; Webb G; McDermott R; Watson W; Crown J; O'Driscoll L
    PLoS One; 2012; 7(12):e50999. PubMed ID: 23251413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
    Corcoran C; Rani S; O'Driscoll L
    Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.
    Kharaziha P; Chioureas D; Rutishauser D; Baltatzis G; Lennartsson L; Fonseca P; Azimi A; Hultenby K; Zubarev R; Ullén A; Yachnin J; Nilsson S; Panaretakis T
    Oncotarget; 2015 Aug; 6(25):21740-54. PubMed ID: 25844599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis.
    Brown SG; Knowell AE; Hunt A; Patel D; Bhosle S; Chaudhary J
    Prostate; 2015 Feb; 75(3):266-79. PubMed ID: 25327819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
    Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
    Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional p53 determines docetaxel sensitivity in prostate cancer cells.
    Liu C; Zhu Y; Lou W; Nadiminty N; Chen X; Zhou Q; Shi XB; deVere White RW; Gao AC
    Prostate; 2013 Mar; 73(4):418-27. PubMed ID: 22996738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer.
    Hanrahan K; O'Neill A; Prencipe M; Bugler J; Murphy L; Fabre A; Puhr M; Culig Z; Murphy K; Watson RW
    Mol Oncol; 2017 Mar; 11(3):251-265. PubMed ID: 28133913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance.
    Bascetta L; Oliviero A; D'Aurizio R; Evangelista M; Mercatanti A; Pellegrini M; Marrocolo F; Bracarda S; Rizzo M
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
    Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
    Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
    Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
    Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73.
    Gao Q; Zheng J
    Biomed Pharmacother; 2018 Jan; 97():528-534. PubMed ID: 29091904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
    Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
    J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
    Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines.
    O'Connell K; Prencipe M; O'Neill A; Corcoran C; Rani S; Henry M; Dowling P; Meleady P; O'Driscoll L; Watson W; O'Connor R
    Proteomics; 2012 Jul; 12(13):2115-26. PubMed ID: 22623417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
    Chao OS; Goodman OB
    Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.
    Kroon J; Puhr M; Buijs JT; van der Horst G; Hemmer DM; Marijt KA; Hwang MS; Masood M; Grimm S; Storm G; Metselaar JM; Meijer OC; Culig Z; van der Pluijm G
    Endocr Relat Cancer; 2016 Jan; 23(1):35-45. PubMed ID: 26483423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells.
    Forde JC; Perry AS; Brennan K; Martin LM; Lawler MP; Lynch TH; Hollywood D; Marignol L
    Urol Oncol; 2012; 30(6):912-9. PubMed ID: 21176881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
    Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
    Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
    Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
    Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.